Held
CNC · Centene Corporation
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 10 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 invalidates the case.
Kill line
A weekly close below $65 ends the September continuation thesis. Withdrawal or reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 independently breaks the fundamental case; failure to close weekly above $68.72 by 2026-10-27 ends the time-bounded thesis.
Pick status
Open commitment catalyst in 4dscored if the kill line above fires How this is scored →Latest analysis and events for CNC —
As of 10 September 2026, the latest FrontierPicks analysis for Centene Corporation (CNC): Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 invalidates the case.
Kill line: A weekly close below $65 ends the September continuation thesis. Withdrawal or reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 independently breaks the fundamental case; failure to close weekly above $68.72 by 2026-10-27 ends the time-bounded thesis.
Next dated event on file: — catalyst in 4d.
Current Thesis
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results, before a weekly close below $65 invalidates the continuation thesis. The adjusted daily close fell to $64.06 on 2026-09-09, following $64.58 on 2026-09-08. Both observations sit below the published weekly threshold; neither establishes a completed weekly breach.
The inference remains that the narrative is maturing — management's guidance increase dates to 2026-07-28, while Stock Analysis now lists Bernstein maintaining its $79 analyst target on 2026-09-09. That advances the date of analyst support without raising the target. A guidance increase accompanied by a weekly close above the $68.72 reference high would overturn this assessment. Analyst table.
Bullish and bearish views on Centene Corporation
The model's bull view on Centene Corporation (CNC), in brief: Quarterly profitability supports the repair. The bear view: Nonrecurring items limit earnings extrapolation. Both cases follow in full.
Bull Case
- Quarterly profitability supports the repair. The 2026-07-28 results reported second-quarter adjusted earnings per share (EPS) of $2.51 and a consolidated health benefits ratio of 89.6%. The ratio measures medical costs relative to premium revenue; the quarter establishes improvement, but the sample is too small to establish durability. Second-quarter results.
- Guidance survived the leadership announcement. Centene reaffirmed fiscal 2026 adjusted EPS guidance above $4.80 on 2026-08-17. Withdrawal or reduction of that guidance would break the fundamental repair argument. August disclosure.
- Analyst support has a newer date. The forecast table updated on 2026-09-09 retains an average analyst target of $71.67 across 21 analysts and lists Bernstein's $79 reiteration that day. These are third-party expectations, not evidence that underwriting has improved since the quarterly release. Analyst table.
Bear Case
- Nonrecurring items limit earnings extrapolation. The 2026-07-28 release attributed approximately $0.50 per share of the guidance increase to nonrecurring Medicare and Commercial items. That contribution does not establish a recurring quarterly earnings rate. Second-quarter results.
- Medicaid repair remains less advanced. The same release reported second-quarter health benefits ratios of 93.9% for Medicaid, 79.2% for Commercial and 89.5% for Medicare. Consolidated improvement therefore does not establish equivalent underwriting performance across the segments. Second-quarter results.
- Officer transactions document selling activity. General Counsel Christopher Koster reported open-market sales dated 2026-08-18 and 2026-08-26 in SEC Form 4 accessions 0001071739-26-000167 and 0001071739-26-000169. The filings establish officer selling; they do not establish motive or broader investor positioning.
Setup & Price Structure
The supplied adjusted daily series records a $64.06 close on 2026-09-09, 6.8% below its $68.72 reference 52-week high. The same snapshot shows a three-month price decline of 2.0% and a 14-day relative strength index of 47.3. No moving-average value or volume series accompanies that snapshot, so distance above a rising average and expanding participation cannot be established.
The $65 weekly invalidation threshold remains the condition published on 2026-09-09; it is not a newly identified support shelf. The latest daily close below that threshold supports low conviction in continuation before invalidation. The supplied daily observations do not resolve the weekly test.
Benzinga's options-activity coverage appeared on 2026-08-25 and 2026-08-27, but the supplied excerpts contain no directional exposure or open-interest figures. Those headlines establish recurring coverage only. The sample is too small to support a crowding claim.
Catalyst Calendar (next 30 days)
- 2026-09-15 — Baird Global Healthcare Conference. Baird confirms the conference date, and Alignment Healthcare's 2026-08-20 announcement confirms its presentation. This is a peer-commentary event; neither source establishes a Centene appearance or resolves Centene's earnings guidance. Baird schedule, Alignment announcement.
- 2026-10-27 — Centene third-quarter results. Beyond the next 30 days, this is the company event on which the thesis turns. Centene's investor-relations homepage lists this date; the test is whether adjusted EPS guidance remains above $4.80 and the required weekly breakout has occurred before invalidation. Company calendar.
The previously listed estimated September-end executive arrival is not an upcoming dated catalyst. The 2026-08-17 filing specified an executive vice-president start on or about 2026-09-01; that expected date has passed, and the filing does not confirm completion. Transition filing.
What Would Change Our Mind
Failure of the published September continuation structure occurs on a weekly close below $65 in the adjusted daily series. The 2026-09-09 daily close of $64.06 puts that condition in focus without proving it has fired. Withdrawal or reduction of the fiscal 2026 adjusted EPS guidance above $4.80, reaffirmed on 2026-08-17, independently breaks the earnings case.
Success requires a weekly close above the $68.72 reference high by the company-listed 2026-10-27 results, with that guidance sustained and no earlier weekly invalidation. If the results date passes without the required breakout, the time-bounded continuation thesis has failed even if earnings guidance survives.
Correlation Notes
FrontierPicks' dated Managed care & health services assessments classified the group as saturated on 2026-08-04, 2026-09-06 and 2026-09-10. That is a group-level research assessment, not measured evidence that Centene itself is crowded. Centene's separate maturing assessment rests on the July guidance increase and September analyst reiteration described above.
The supplied peer set includes HUM, OSCR, AVAH and HNGE, but no paired return series accompanies the 2026-09-09 price snapshot. Numerical correlations and the strength of any common market factor are therefore unmeasured. Alignment's confirmed 2026-09-15 presentation supplies a dated peer observation; Centene's own guidance and published close conditions remain the tests of its thesis.
Notes
- Adjusted EPS excludes amortization of acquired intangibles and other items: FY2026 GAAP guidance is more than $3.11 against adjusted more than $4.80.
- FY2025 carried a $6,723M goodwill impairment, a $513M Magellan impairment and a $(13.53) GAAP diluted loss, so trailing GAAP earnings stay negative until that quarter rolls off.
- Marketplace risk-adjustment transfers settle with a lag, so prior-benefit-year true-ups can swing a single quarter's EPS by tens of cents either way.
- Premium and service revenue ran $44.4B in Q2 2026 on a thin underwriting spread; point moves in the health benefits ratio dominate EPS more than membership headlines.
- Calendar fiscal year: Q3 results are listed by the company for 2026-10-27, with some third-party calendars carrying 2026-10-28; full-year results land in early February.
- Revenue is set largely by state Medicaid rate cycles and CMS rulemaking, so regulatory calendar dates move the P&L more than company-level execution.
Related · shared themes
HUM
Humana Inc.
Humana's Medicare Advantage margin reset supports continuation above the $409.42 adjusted reference high before a daily close below $383. Bernstein maintained its $425 analyst target on 2026-09-09, while October Star Ratings leave the 2028 operating objective unresolved.
OSCR
Oscar Health, Inc.
Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the specified growth framework also ends the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
CXW
CoreCivic, Inc.
DHS is buying CoreCivic's detention real estate outright — $2.2B gross for four facilities, about $307k/bed — while CoreCivic keeps operating them; proceeds funded $608.5M of debt repayment and a $500M buyback expansion (2026-08-05 release). Shares closed 2026-09-04 at a 52-week high of $34.71 with RSI 56.4, and no company-dated catalyst falls inside the next 30 days.
See also · stocks to watch